Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:45 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 13,351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intracranial CNS Disorder Clear all
Active, not recruiting Phase 2 Interventional

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

NCT04218968
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
Interventions
Carvedilol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 1Phase 2 Interventional

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

NCT03277638
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
Pembrolizumab at 7 days prior, Pembrolizumab at 14 days post, Pembrolizumab at 35 days post, Laser Interstitial Thermotherapy
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Completed No phase listed Observational Accepts healthy volunteers

The Benefits of Nature for Mood and Cognition in Persons With and Without Parkinson's Disease

NCT06483126
View directory record Official record
Conditions
Parkinson Disease, Mood, Cognition
Interventions
Not listed
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
40 Years to 100 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 1 Interventional

Intranasal Glutathione in Parkinson's Disease

NCT01398748
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Intranasal glutathione - (in)GSH, Saline Intranasal Delivery
Drug
Lead sponsor
Bastyr University
Other
Eligibility
21 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Nov 1, 2026, 4:45 AM EST
Completed No phase listed Observational

A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits

NCT02778438
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Quintiles, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 4 Interventional Results available

Amitiza in Constipation Associated With PD (Parkinson's Disease)

NCT00908076
View directory record Official record
Conditions
Parkinson's Disease
Interventions
LUBIPROSTONE
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Nov 1, 2026, 4:45 AM EST
Recruiting Not applicable Interventional

Dysphagia Study Using Novel Microphone Device

NCT07251140
View directory record Official record
Conditions
Dysphagia, Stroke
Interventions
Microphone device
Device
Lead sponsor
Emory University
Other
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Withdrawn Phase 3 Interventional

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2008 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 1 Interventional

Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

NCT01480050
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, 3'-deoxy-3'-[18F]fluorothymidine, pharmacological study, Mibefradil
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

NCT01912391
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Selegiline, Placebo (for Selegiline)
Drug
Lead sponsor
Mood and Anxiety Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Nov 1, 2026, 4:45 AM EST
Completed Not applicable Interventional

Acute Probiotic Supplementation and Endothelial Function

NCT04364074
View directory record Official record
Conditions
Coronary Artery Disease, Hypertension, Hyperlipidemias, Peripheral Vascular Diseases, Cerebral Arterial Diseases
Interventions
Goodbelly, Placebo
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Nov 1, 2026, 4:45 AM EST
Recruiting Phase 2 Interventional

Long-Term Outcomes Following HBOT

NCT07732374
View directory record Official record
Conditions
Traumatic Brain Injury, Post-Concussive Symptoms, Post-Traumatic Stress Disorder
Interventions
Hyperbaric Oxygen Therapy (HBOT)
Drug
Lead sponsor
Summit Hyperbarics and Wellness
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Not listed No phase listed Observational

LONG TERM EFFECTS OF SPINAL CORD STIMULATION

NCT06272955
View directory record Official record
Conditions
Parkinson Disease
Interventions
Spinal Cord Stimulator (SCS)
Device
Lead sponsor
Nora Vanegas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 1 Interventional

Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

NCT02709226
View directory record Official record
Conditions
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
Interventions
Radiation
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Completed Not applicable Interventional Results available

Post-stroke Pain taVNS

NCT06456385
View directory record Official record
Conditions
Stroke, Pain
Interventions
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham Auricular Stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 2 Interventional Results available

Staccato Alprazolam and Photoparoxysmal Response

NCT02351115
View directory record Official record
Conditions
Epilepsy
Interventions
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 m, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Boise, Idaho • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Completed Not applicable Interventional

Spatiotemporal Dynamics of the Human Emotion Network

NCT05152992
View directory record Official record
Conditions
Epilepsy, Depression, Anxiety, Emotions
Interventions
Viewing visual stimuli and electrical stimulation of the brain
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Recruiting No phase listed Observational

Longitudinal Endpoint Assessment of Disease Burden in HD

NCT06475898
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
Huntington Study Group
Network
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of DA-9805 for Parkinson's Disease

NCT03189563
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DA-9805 45mg, DA-9805 90mg, Placebo
Drug · Other
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
30 Years to 79 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Nov 1, 2026, 4:45 AM EST
Active, not recruiting Not applicable Interventional

Brain Stimulation for Improving Cognition in Chronic Stroke (NEPTUNE)

NCT04655963
View directory record Official record
Conditions
Chronic Stroke
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 1, 2026, 4:45 AM EST
Completed Not applicable Interventional Results available

taVNS in Mild to Moderate Parkinson's Disease

NCT04157621
View directory record Official record
Conditions
Parkinson Disease
Interventions
Active taVNS, Sham Stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Nov 1, 2026, 4:45 AM EST
No Longer Available No phase listed Expanded access

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

NCT05064306
View directory record Official record
Conditions
Central Nervous System/Leptomeningeal Neoplasms
Interventions
131I-omburtamab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Nov 1, 2026, 4:45 AM EST
Terminated Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT02220738
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-957, Placebo for ABT-957
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Glendale, California • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Nov 1, 2026, 4:45 AM EST
Recruiting Phase 1 Interventional

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

NCT04789148
View directory record Official record
Conditions
Vasopressin Deficiency
Interventions
Intranasal Oxytocin (IN-OXT) 6 IU single dose, Intranasal Oxytocin (IN-OXT) 6 IU repeat dose, Placebo repeat dose, Intranasal Oxytocin (IN-OXT) 24 IU single dose, Placebo single dose
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 4:45 AM EST